Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
ORKA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.61 - $53.88
Previous CloseN/A
Volume71.58K
Average Volume (3M)307.47K
Market Cap
$394.78M
Enterprise Value$13.87M
Total Cash (Recent Filing)21.16M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.14
Next Earnings
May 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 29, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-6.68
Shares Outstanding34,998,550
10 Day Avg. Volume322,081
30 Day Avg. Volume307,471
Standard Deviation0.37
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-37.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.75Price Target Upside251.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Oruka Therapeutics News
PremiumCompany Announcements
Oruka Therapeutics: Strong Q3 and Strategic Advances---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressOruka announced that the company has successfully dosed its first volunteers in the Phase 1 study of its lead candidate, ORKA-001, marking a significant milestone for the company.
Earnings PotentialHalf-life extension could enable ORKA-002 to capture a meaningful slice of the pie, implying a lucrative market opportunity, if ultimately successful.
Therapeutic AdvancementsORKA-001's differentiation is superior pharmacokinetics, as demonstrated in preclinical data, showing a non-human primate half-life significantly longer than a leading competitor's product.
Bears Say
Development TimelineManagement reaffirmed that pharmacokinetic and safety data for ORKA-001 are expected in the second half of 2025, indicating ongoing progress in the clinical trial.
Financial CommitmentsAs part of the deal, ORKA will pay up to $22M in milestone payments.
Market CompetitionIL-17A/F inhibition is new to the commercial setting, with Bimzelx garnering FDA approval in October 2023 for use in patients with moderate-to-severe plaque psoriasis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORKA FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Oruka Therapeutics lowest stock price was $10.61 and its highest was $53.88 in the past 12 months.
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $394.78M.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 74 days.
How were Oruka Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics pays a Notavailable dividend of $19.08 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 34,998,550 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in ORKA
---
Oruka Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.75 (251.63% Upside)
$38.75 (251.63% Upside)
Blogger Sentiment
Bullish
ORKA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.97%
12-Months-Change
Fundamentals
Return on Equity
-15.88%
Trailing 12-Months
Asset Growth
956.78%
Trailing 12-Months
Company Description
Oruka Therapeutics
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
---
ORKA Stock 12 Month Forecast
Average Price Target
$38.75
▲(251.63% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Incyte
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering ORKA
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-34.58%
reiterated a buy rating 16 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.58% per trade.
---